Abstract:Background: Accumulating evidence indicates that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower glucose mainly by enhancing glucose-dependent stimulation of insulin secretion. However, the underlying mechanisms remain to be further investigated. Methods: C57BL6/J mice fed with 12-week high-fat diet (HFD) were treated with exenatide (a GLP-1 RA, 24nmol/kg/d), GW501516 (a PPARΔ agonist, 2mg/kg/d) or saline injection as control for 8 weeks. Phenotypic evaluations were performed during and after the intervention. Tolerance tests and insulin measurement were performed after 8-week treatment. The mouse pancreatic β-cell line MIN6 was used as an in vitro model. The MIN6 cells were treated with GW501516 (10uM), exendin-4 (a GLP-1 RA, 20nM) combined with GSK0660 (a PPARΔ antagonist, 10uM) or not. Furthermore, mediums containing various concentrations of exendin-4 (1, 20 and 100 nM) or GW501516 (0.1, 1, 10 and 100uM) were applied. And the cells were incubated for 24 hours. PPARΔ and uncoupling protein-2 (UCP-2) protein expression were detected. Results: Compared with the control group, exenatide and GW501516 treatment led to decreased body weight and improved insulin sensitivity in HFD mice. The mice in control group had higher serum insulin levels during the tolerant tests, but their early-phase insulin secretion was lacking, indicating the impaired insulin sensitivity and β-cell function. Both exenatide and GW501516 decreased the serum insulin levels in the HFD mice. Importantly, the lacking early-phase insulin secretion were recovered by both exenatide and GW501516. The protein expression of PPAR Δ was promoted while that of UCP-2 was decreased by exendin-4 in a dose-dependent manner. Similar results were found in cells treated with GW501516. However, these salient effects were partly reversed by GSK0660. Conclusions: The effect of the GLP-1 RA exenatide on promoting β-cell function might be related to the activation of PPARΔ/UCP-2 pathway. Disclosure Y. Su: None. W. Xu: None. B. Lin: None. Z. Liu: None. Y. Chen: None. Z. Ye: None. L. Gan: None. B. Yao: None. Funding National Natural Science Foundation of China (81770821 to W.X.)

Improved leptin sensitivity and increased soluble leptin receptor concentrations may underlie the additive effects of combining PYY [, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ] and exendin-4 on body weight lowering in diet-induced obese mice

GLP-1 and PYY for the treatment of obesity: use of agonists and antagonists in diet-induced rats, a pilot study

Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist

Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss

Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner

Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy

Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Effect of GLP-1 receptor agonist on lipolysis in adipose tissue of obese mice and its underlying mechanism

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice

Systemic co-administration of low dose oxytocin and glucagon like peptide-1 additively decreases food intake and body weight

Effects of a long-acting secretin peptide analog alone and in combination with a GLP-1R agonist in a diet-induced obesity mouse model

Interaction of Dietary Composition and PYY Gene Expression in Diet-Induced Obesity in Rats.

2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

The Anorexic Effect of Ex4/Fc Through Glp-1 Receptor Activation in High-Fat Diet Fed Mice

A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss

Exendin-4 Improves Fat Metabolism of Brown Adipose Tissue in High-Fat Diet-Induced Obese C57BL/6J Mice

Decoy bypass for appetite suppression in obese adults: role of synergistic nutrient sensing receptors GPR84 and FFAR4 on colonic endocrine cells

GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans